Delivery Order SPE2DB24D2216-SPE2DB25FGPVF
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 5, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract, valued at $11,989.73, carries a firm fixed price and is classified as a non-set-aside, competitively awarded procurement. The delivery order is scheduled for completion by September 8, 2025, with the place of performance...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on August 8, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This firm fixed-price delivery order, valued at $3,138.37, was competitively awarded without set-aside designation and is scheduled for completion by August 11, 2025. The order will be fulfilled from the vendor's location in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 19, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL injections valued at $7,156.00. The award was made by the Defense Logistics Agency under a firm fixed-price contract structure with no set-aside designation, indicating competitive award status. The order is scheduled for completion by August 20, 2025, with performance at...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 27, 2025, valued at $8,937.86 for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials. This competitive, non-set-aside contract is funded through the Defense Logistics Agency's Medical Supply Chain division and is set to be completed by August 28, 2025. The delivery order will be fulfilled at AmerisourceBergen's corporate office location in...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $11,268.23 delivery order on August 26, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed-price contract was funded by the Defense Logistics Agency under the Department of Defense and will be fulfilled at the vendor's Conshohocken facility, with an ultimate completion date of August 27, 2025. The award represents a child contract under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 25, 2025, by the Defense Logistics Agency to supply Ozempic 2 mg/dose (8 mg/3 ml) injectable medication. The contract, valued at $14,490.85, represents a firm fixed price delivery order with an ultimate completion date of August 26, 2025. This award was not designated as a set-aside contract and was competitively awarded through open competition. The...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order contract by the Defense Logistics Agency (DLA) on August 20, 2025, valued at $9,486.77. The contract calls for the delivery of Ozempic 0.25–0.5 mg/dose pens (3 mL) to support federal medical supply requirements. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and is scheduled for ultimate completion by August 21, 2025, with...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on July 21, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed-price delivery order has a ceiling value of $28,322.36 and an ultimate completion date of July 22, 2025. The contract carries no set-aside designation, indicating it was competed among qualified vendors through open...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 15, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract is a firm fixed-price delivery order with a ceiling value of $1,784.73 and an ultimate completion date of September 16, 2025. The place of performance is located in Conshohocken, Pennsylvania, the company's corporate headquarters. This award was competitively awarded with no set-aside designation and...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract is valued at $3,759.96 and carries a firm fixed price with an ultimate completion date of August 19, 2025. The award utilized competitive procurement procedures with no set-aside designation. The place of performance is identified as the vendor's corporate office in Conshohocken, Pennsylvania. This...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPVFDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 18, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. The delivery order, valued at $33,789.66, represents a firm fixed price contract with an ultimate completion date of September 19, 2025, and was competitively awarded with no set-aside designation. Performance will occur at the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor contract valued at $999,999,999.00 and extending through December 2026. The parent IDC enables the company to supply a broad range of pharmaceuticals, medical devices, and healthcare commodities to support military and federal healthcare systems globally. The Ozempic procurement supports the Defense Health Agency and other federal healthcare customers requiring diabetes management medications within the DLA Medical Supply Chain framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $33.8k | 9/18/25 |